Indrayani Biotech (BOM:526445) Cyclically Adjusted Revenue per Share: ₹55.69 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:526445 Indrayani Biotech Ltd BOM:526445
53 GF Score
Price ₹7.86
GF Value ₹41.65
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Indrayani Biotech Cyclically Adjusted Revenue per Share?

Indrayani Biotech BOM:526445 +4.80% 53 Cyclically Adjusted Revenue per Share is ₹55.69 as of Dec. 2025. GuruFocus rates BOM:526445 with a GF Score™ of 53/100 and a GF Value™ of ₹41.65 (Possible Value Trap). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Indrayani Biotech's adjusted revenue per share for the three months ended in Dec. 2025 was ₹7.689. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹55.69 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Indrayani Biotech's average Cyclically Adjusted Revenue Growth Rate was -4.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-16), Indrayani Biotech's current stock price is ₹7.86. Indrayani Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was ₹55.69. Indrayani Biotech's Cyclically Adjusted PS Ratio of today is 0.14.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Indrayani Biotech was 1.50. The lowest was 0.13. And the median was 0.77.


Indrayani Biotech  (BOM:526445) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Indrayani Biotech's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.86/55.69
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Indrayani Biotech was 1.50. The lowest was 0.13. And the median was 0.77.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Indrayani Biotech Cyclically Adjusted Revenue per Share Related Terms


Indrayani Biotech Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Indrayani Biotech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indrayani Biotech Cyclically Adjusted Revenue per Share Chart

Indrayani Biotech Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 64.62 61.91 57.33

Indrayani Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.22 57.33 56.57 56.39 55.69

BOM:526445 vs CTAS, CPRT, GPN: Cyclically Adjusted Revenue per Share Comparison

For the Specialty Business Services subindustry, Indrayani Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indrayani Biotech Cyclically Adjusted PS Ratio vs Business Services Industry

For the Business Services industry and Industrials sector, Indrayani Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Indrayani Biotech's Cyclically Adjusted PS Ratio falls into.


BOM:526445
53GF Score
Indrayani Biotech Ltd BOM:526445
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indrayani Biotech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Indrayani Biotech's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=7.689/163.2808*163.2808
=7.689

Current CPI (Dec. 2025) = 163.2808.

Indrayani Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 0.000 102.518 0.000
201606 0.000 105.961 0.000
201609 0.000 105.961 0.000
201612 0.000 105.196 0.000
201703 0.000 105.196 0.000
201706 0.000 107.109 0.000
201709 0.000 109.021 0.000
201712 0.000 109.404 0.000
201803 0.000 109.786 0.000
201806 0.000 111.317 0.000
201809 0.000 115.142 0.000
201812 0.000 115.142 0.000
201903 0.000 118.202 0.000
201906 0.000 120.880 0.000
201909 0.000 123.175 0.000
201912 1.377 126.235 1.781
202003 133.033 124.705 174.185
202006 0.998 127.000 1.283
202009 1.205 130.118 1.512
202012 1.697 130.889 2.117
202103 1.799 131.771 2.229
202106 4.437 134.084 5.403
202109 4.284 135.847 5.149
202112 4.661 138.161 5.508
202203 4.661 138.822 5.482
202206 7.450 142.347 8.546
202209 12.319 144.661 13.905
202212 10.667 145.763 11.949
202303 11.156 146.865 12.403
202306 12.362 150.280 13.431
202309 11.815 151.492 12.734
202312 8.771 152.924 9.365
202403 9.619 153.035 10.263
202406 6.924 155.789 7.257
202409 6.767 157.882 6.998
202412 3.629 158.323 3.743
202503 11.105 157.552 11.509
202506 5.579 159.755 5.702
202509 7.895 162.289 7.943
202512 7.689 163.281 7.689

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹55.69 mean?
Indrayani Biotech (BOM:526445) has a Cyclically Adjusted Revenue per Share of ₹55.69 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Indrayani Biotech and its competitors.
Is Indrayani Biotech's Cyclically Adjusted Revenue per Share too high?
Indrayani Biotech's current Cyclically Adjusted Revenue per Share is ₹55.69. Overall, Indrayani Biotech has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indrayani Biotech's Cyclically Adjusted Revenue per Share compare to CTAS and CPRT?
Indrayani Biotech's Cyclically Adjusted Revenue per Share of ₹55.69 can be compared against companies in the Business Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Business Services company?
A good Cyclically Adjusted Revenue per Share depends on the Business Services industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Indrayani Biotech and its competitors. Indrayani Biotech's current Cyclically Adjusted Revenue per Share is ₹55.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indrayani Biotech stock overvalued right now?
Based on GuruFocus' analysis, Indrayani Biotech (BOM:526445) is currently considered Possible Value Trap. The stock's GF Value™ is ₹41.65, compared to a current price of ₹7.86 — trading 81.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹55.69. Indrayani Biotech's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Indrayani Biotech (BOM:526445), the current Cyclically Adjusted Revenue per Share is ₹55.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indrayani Biotech (BOM:526445) Overvalued in 2026?

Based on GuruFocus' analysis, Indrayani Biotech stock appears to be undervalued. The current stock price of ₹7.86 is trading 81.1% below its estimated GF Value™ of ₹41.65. GuruFocus considers Indrayani Biotech to be Possible Value Trap.

Key valuation signals for BOM:526445:

  • Cyclically Adjusted Revenue per Share: ₹55.69
  • GF Value™: ₹41.65 vs. price of ₹7.86 (81.1% below fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the BOM:526445 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Indrayani Biotech Business Description

Address Module No. 33, Block 1, 3rd Floor, SIDCO Electronic Complex, Thiru-vi-ka Industrial Estate, Guindy, Chennai, TN, IND, 600032
Indrayani Biotech Ltd operates in the Tri-segment i.e. Foods & Hospitality, Engineering and Healthcare divisions. The company generates its revenue from the sale of food, beverages, and other items; the Sale of Engineering products & Others. The majority of its revenue is generated from the sale of food, beverages, and other items.
53GF Score

Get the complete analysis for BOM:526445

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹7.86
Price
₹41.65
GF Value